Clinical Trial Update: SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study [Phase 2]

View source ↗

Summary

Phase 2 open-label pilot study of MD1003 (serendem) in demyelinating neuropathies completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-mag Neuropathy
• Charcot-marie-tooth Disease
• Charcot-marie-tooth Disease Type 1a
• Charcot-marie-tooth Disease Type 1b
• Inflammatory Demyelinating Polyneuropathy
• Peripheral Neuropathy

Drugs mentioned

• MD1003 (biotin (high-dose))

Snippet

Sponsor: MedDay Pharmaceuticals SA | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy | Phase 2 | Status: COMPLETED | Results posted: 2020-11-02